Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has swung higher to the tune of almost 8%. Interestingly, Friday’s afterhours ...

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly ...

For anyone who wants to understand Gilead Sciences' profit beyond the statutory numbers, it's important to note that during ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...